Search
News
Earnings
Olin Q3 2026 Earnings: Sales Edge Higher as Profit Falls
Olin Corporation’s Q3 2026 sales rose about 2.0% year over year to $1.75 billion, but diluted EPS fell to $0.13 from $0.37 and adjusted EBITDA declined 13.9% to $191.4 million. Growth in Epoxy and Winchester did not fully offset lower Chlor Alkali Products and Vinyls earnings, which were hurt by VCM operating issues and a smaller hydrogen tax-credit benefit. Olin expects Q4 adjusted EBITDA of $80 million to $100 million as customer destocking, higher feedstock costs, Asian export pressure, and planned maintenance weigh on the near-term outlook.
TradingKey
Thu, Oct 29
Earnings
Rocket Companies Q3 2026 Earnings: Mortgage Profitability Drives a Return to GAAP Profit
Rocket Companies’ Q3 2026 earnings showed a return to GAAP profitability as total net revenue rose to $3.28 billion from $1.70 billion and diluted EPS reached $0.25 versus a $0.06 loss. Adjusted revenue increased to $2.57 billion, while adjusted EBITDA more than doubled to $748 million. Mortgage contribution margin rose to $1.14 billion, reflecting improved direct profitability, although a $710 million MSR-related valuation benefit widened the gap between GAAP and adjusted results. Rocket guided Q4 adjusted revenue to $2.1 billion–$2.3 billion.
TradingKey
Thu, Oct 29
Earnings
DaVita Q3 2026 Earnings: China Impairment Pressures Operating Margin
DaVita’s Q3 2026 revenue rose 4.6% year over year to $3.578 billion, while diluted EPS increased to $3.40 from $2.04. GAAP operating income slipped to $499 million and margin fell to 14.0%, reflecting a $62 million noncash impairment tied to China; adjusted operating income was $561 million. Operating cash flow declined to $519 million from $842 million, and free cash flow fell to $276 million. The company raised the low ends of its 2026 adjusted operating income and adjusted EPS guidance while leaving free cash flow guidance unchanged.
TradingKey
Thu, Oct 29
Earnings
Penumbra Q3 2026 Earnings: Revenue Rises 15.6% as EPS Declines
Penumbra (NYSE: PEN) reported Q3 2026 revenue of $410.1 million, up 15.6%, while diluted EPS declined to $1.07 from $1.17. Global thrombectomy revenue increased 18.1% to $279.2 million, and gross margin expanded 0.5 percentage points to 68.3%. Operating expenses rose to $229.6 million, including $7.1 million in acquisition-related costs, while net income fell to $42.3 million. The pending Boston Scientific acquisition also led Penumbra to withhold full-year guidance and cancel its quarterly conference call.TradingKey
Thu, Oct 29
Economic Indicator
Philippine Peso: Official jawboning slows depreciation – OCBC
OCBC’s Sim Moh Siong and Christopher Wong note that the Philippine Peso (PHP) has recovered modestly as authorities, including President Marcos and Bangko Sentral ng Pilipinas (BSP) officials, step up rhetoric against further weakness.Fxstreet
Thu, Oct 29
Featured Tools
Top News
DomoAI Launches InkoAI Agent - One Sentence to Ready-to-Post Video
【US Pre-Market】Nvidia Rebounds Over 2%; Microsoft Falls Over 2% Amid Massive Global Outage; October PPI Due
Nasdaq Extends Drop by 0.91% as Tech Stocks Lead Declines, AMD Falls Nearly 9%, Nvidia Drops 2%
Gold Price Forecast: Gold Tumbles Below $3,900 as Trump Says No Need for Iran Deal; Can October PPI Spur a Rebound?
US October PPI Preview: Fed Rate Hike Expectations Rise, PPI May Be Key Variable; How Will US Stocks, Dollar, and Gold Move?
